Lyell Immunopharma is a T cell reprogramming company that develops T cell therapies for solid tumors using the Gen-R and Epi-R technology platforms to overcome T cell exhaustion and generate T cells with durable stemness. Its pipeline includes LYL797 for non-small cell lung cancer and triple negative breast cancers, LYL845 targeting multiple solid tumors, and NY-ESO-1 for synovial sarcoma and other solid tumor indications, with the latter being developed in collaboration with GlaxoSmithKline.
Frequently asked questions
Is Lyell Immunopharma (LYEL) stock halal to invest in?
As of , LYEL is not Shariah-compliant and is therefore not considered a halal investment. This assessment is based on the data available in Lyell Immunopharma's most recent financial reports.
Does Lyell Immunopharma have any interest income?
Yes, Lyell Immunopharma does have interest income. According to the company's latest annual report for
the fiscal year ending Dec 31, 2025, Lyell Immunopharma reported revenue of
$36,000 and interest income of
$13,080,000. The interest income represents
36333.33% of the combined total. It's worth noting that some companies
may report additional interest income as part of their revenue. For a detailed breakdown of all interest
income and revenue segments, please refer to the full Shariah compliance report available in the Zoya app.
What guidelines are used to determine if Lyell Immunopharma stock is Shariah-compliant?
We use the guidelines set by the Accounting and Auditing Organization for Islamic Financial Institutions
(AAOIFI) to assess Shariah compliance. AAOIFI is a leading international organization that establishes
standards for Islamic finance. Their guidelines help determine if a company's business activities and
financial structure align with Islamic principles. These standards are widely respected in the Islamic
finance industry and provide a consistent framework for evaluating the Shariah compliance of stocks and
other financial instruments. AAOIFI's Shariah board includes renowned scholars such as Sheikh Muhammad
Taqi Usmani, Sheikh Mohamed Ali Elgari, Sheikh Abdullah AlManea, Sheikh Nizam Yaquby, and Dr. Aznan Hassan.
How often is Lyell Immunopharma stock reviewed for Shariah compliance?
The Shariah compliance status of Lyell Immunopharma stock is reviewed on a regular basis, with a minimum
frequency of once per quarter. However, if there are any significant changes or major developments
in the company's operations that may impact its compliance, an immediate review will be conducted to
ensure ongoing adherence to Shariah principles.
How can I stay updated on Lyell Immunopharma's compliance status?
To stay informed, we recommend regularly checking Zoya for updates. You can also enable alerts within
the Zoya app to receive notifications whenever there is a change in the Shariah compliance of LYEL,
or any other stocks you are monitoring. This is particularly useful as Shariah compliance can fluctuate
due to changes in a company's financial ratios or business activities.
Are dividends from Lyell Immunopharma stock considered halal?
No, dividends from LYEL are not considered halal because the stock is currently not
Shariah-compliant. When a stock is non-compliant, any dividends received from it are considered
impermissible income and should be donated to charity as a form of purification. To learn more about
the purification process and how to handle impermissible income, read
our comprehensive guide.
Do I need to pay Zakat on my Lyell Immunopharma shares?
If you hold Lyell Immunopharma stock as an investment, through an Employee Stock Ownership
Plan (ESOP), stock options, restricted stock units (RSUs), or any other form of stock ownership, and
meet the Nisab threshold, you may be required to pay Zakat on it. The calculation of Zakat on investments
can be complex and depends on various factors. To help make this easy, we've created a free
Zakat calculator for stocks. For a more
seamless experience, use the Zoya mobile app, where you can link your brokerage account to
automatically import holdings.
Community posts
Related stocks
See how Lyell Immunopharma compares with its peers:
